Cardio Diagnostics (CDIO) director granted 2,306 stock options at $2.71

Rhea-AI Filing Summary

Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award. On 12/31/2025, he was granted 2,306 stock options (right to buy common stock) with a conversion or exercise price of $2.71 per share. After this grant, he beneficially owns 7,259 derivative securities in the form of stock options, held in direct ownership. The filing was made on Form 4 for a single reporting person, reflecting an option grant coded as an acquisition.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Burton Paul Frederick

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	2,306	$2.71	$6K

Holdings After Transaction: Stock Options (Right to Buy) — 7,259 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burton Paul Frederick

(Last) (First) (Middle)

C/O CARDIO DIAGNOSTICS HOLDINGS INC.

311 W. SUPERIOR ST. SUITE 444

(Street)

CHICAGO IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.71	12/31/2025		A		2,306		12/31/2025	12/31/2035	Common Stock	2,306	$2.71	7,259	D

Explanation of Responses:

	/s/ Elisa Luqman as attorney-in-fact for Paul Burton	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cardio Diagnostics (CDIO) report on this Form 4?

The Form 4 reports that director Burton Paul Frederick received an award of 2,306 stock options (right to buy common stock) on 12/31/2025 at an exercise price of $2.71 per share.

Who is the reporting person in this Cardio Diagnostics (CDIO) Form 4 filing?

The reporting person is Burton Paul Frederick, who is identified as a director of Cardio Diagnostics Holdings, Inc. and is filing individually as one reporting person.

How many Cardio Diagnostics stock options does the director hold after this transaction?

Following the reported stock option grant, Burton Paul Frederick beneficially owns 7,259 derivative securities in the form of stock options related to Cardio Diagnostics common stock.

What are the key terms of the stock options granted to the Cardio Diagnostics director?

The grant consists of 2,306 stock options with a $2.71 exercise price per share, exercisable into Cardio Diagnostics common stock, with an expiration date of 12/31/2035 as shown in the table.

Is the Cardio Diagnostics director’s ownership in these options direct or indirect?

The Form 4 indicates that the 7,259 stock options are held in direct (D) ownership by Burton Paul Frederick, with no separate nature of indirect beneficial ownership listed.

Does this Form 4 involve non-derivative Cardio Diagnostics securities?

The excerpted filing shows activity only in derivative securities, specifically stock options, and does not list any transactions in non-derivative Cardio Diagnostics securities in the provided tables.